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Invited Commentary | Oncology
Less Is More in Lung Cancer Risk PredictionModels
Marjolein A. Heuvelmans, MD, PhD; Matthijs Oudkerk, MD, PhD
Screening of high-risk individuals by low-dose chest computed tomography (CT) reduces lung cancer
mortality, as has been shown by 2 large randomized clinical trials.1,2 Contrary to other cancer
screening programs, such as breast and colorectal cancer screening, individuals eligible for screening
are not selected only based on sex and age. Lung cancer is in most cases diagnosed in (former)
smokers. To increase the efficacy of a screening program, and tominimize harms to individuals at low
risk of the disease, it is most cost-effective to invite only those individuals who have the highest risk
of developing lung cancer to undergo annual low-dose chest CT. Risk prediction models aim to assist
in identifying these high-risk individuals, andmost international lung cancer screening guidelines
recommend using amodel to optimize selection of the screening population.3
In addition to predictionmodels for the identification of the population at risk, in recent years,
a variety of models have been published predicting lung nodule malignancy risk in screen-detected
pulmonary nodules. These lung nodule malignancy risk prediction models aim to improve decision-
making regarding nodule management and diagnosis. In every second lung cancer screening
participant, at least 1 lung nodule is detected at the baseline screening round. A quarter of those who
undergo screening present with 2 or more baseline nodules.4 At nodule level, fewer than 1% are
diagnosed as lung cancer; the others are likely to represent benign lesions such as scars or
intrapulmonary lymph nodes.
Lung nodule malignancy predictionmodels are based either on data collected in screening
studies (ie, different versions of themodel used in the Pan-Canadian Early Detection of Lung Cancer
Study [also referred to as the Brock model]5 and the model using data from the UK Lung Cancer
Screening [UKLS] trial6) or on clinically, mostly incidentally, detected nodules (ie, models from the
Mayo Clinic, the US Department of Veteran Affairs clinics, and Peking University People’s Hospital).
In the study by González Maldonado et al,7 performance of these lung nodule malignancy
predictionmodels was externally tested using data from the interventional group of the German
Lung Cancer Screening Intervention (LUSI) randomized clinical trial. In total, 1159 participants with
3903 noncalcified lung nodules in any of 5 annual low-dose CT screening rounds were selected for
this study. During the active screening period, 54 of 1159 participants with nodules (5%) were
diagnosed with lung cancer. Most lung nodules were detected at baseline (2883 nodules [73.9%]),
whereas half of the lung cancers were diagnosed in 1 of the 1020 nodules newly detected after
baseline. In the rounds following baseline screening, 80.6% of lung cancers had diameter of at least
8mm at diagnosis.
González Maldonado et al7 have shown that performance of all 8 predictionmodels was better
on prevalence (baseline) nodules compared with nodules newly detected during incidence
screenings. Previous studies have shown that lung nodule malignancy risk differs between nodules
present at baseline and new nodules. In general, new nodules identified at incidence screening are
relatively young and fast growing whereas baseline nodules might have been present for years. This
leads to a substantially lower overall lung cancer probability at baseline.8 Therefore, new nodules
are managed differently from baseline nodules in established guidelines.3 This study shows that a
different model for prediction of risk for malignant nodules should be developed for lung nodules
newly detected after the baseline screening round.
Focusing on themodels that were generated based on screening data, the different versions of
the Pan-Canadian model outperformed the UKLSmodel. Sometimes less is more. In case a model
includes parameters with high risk of interreader variability, such as diagnosis of bronchitis or
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discrimination between part-solid and nonsolid lung nodules in the UKLSmodel,6 transferability to
other cohorts could be improper. González Maldonado et al7 showed significantly better
performance of the UKLS model in the LUSI data set after excluding parameters prone to volatility
from themodel.
Before drawing conclusions about the optimal lung nodule malignancy risk predictionmodel for
lung nodule management in low-dose CT lung cancer screening based on this feasibility study, it is
important to realize the study’s limitations. In the LUSI trial, nodule size was determined based on
3-dimensional nodule segmentation instead of manual caliper measurements in the axial plane,
leading to more precise and reproducible diameter measurements. Performance of themodels in a
manual nodule diameter-based lung cancer screening trial is expected to be worse. Furthermore,
using semi–3-dimensional nodule measurements (diameter based on the nodule in 3 dimensions)
might have masked a difference in performance of the diameter and volume versions of the Pan-
Canadianmodel.
What are themain messages from the feasibility study of González Maldonado and colleagues7
on different lung nodule malignancy risk prediction models in an external low-dose chest CT lung
cancer screening data set? First, this study showed the importance of external testing of risk
predictionmodels. It found that the original results of some risk predictionmodels cannot be
repeated in an external set. One reason, as illustrated by González Maldonado et al,7 might be
inclusion of parameters prone to high volatility in a risk predictionmodel, reducing the transferability
to an external data set. Second, the sharply reducedmodel performance when using the different
models on nodules newly detected after baseline confirms the need of separate management for
new nodules. This is also true with respect to nodule malignancy risk predictionmodels.
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